Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 30;2021(3):e202118.
doi: 10.21542/gcsp.2021.18.

Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre

Affiliations
Review

Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre

Ioanna Istampoulouoglou et al. Glob Cardiol Sci Pract. .

Abstract

In this article we summarize suspected adverse events following immunization (AEFI) of pericarditis, myocarditis and perimyocarditis that were reported by our regional pharmacovigilance centre after COVID-19 mRNA-vaccination and discuss their association with these vaccines. Seventeen cases were reported between March and July 2021. Of these, nine had perimyocarditis, five myocarditis and three pericarditis. Twelve patients were male (71%). The median age was 38 years (range 17-88). The most commonly observed presenting symptom was acute chest pain (65%). While 47% of the patients were previously healthy, 53% had at least one pre-existing comorbidity, with hypertension being the most prevalent (24%). The European Society of Cardiology diagnostic criteria for the reported AEFIs were fulfilled in twelve cases (71%). The AEFIs occurred after the first vaccine dose in six cases (35%), after the second vaccine dose in ten cases (59%) and after both doses in one case (6%). The median latency of all AEFIs taken together was 14 days (range 1-28) after the first vaccination and 3 days (range 1-17) after the second one. All patients except one were hospitalized (94%) with a median length of stay of 7.5 days (range 3-13). The majority of patients (n = 11, 65%) did not experience any complications, and 13 (77%) of the patients had recovered or were recovering at the time of discharge. In 16 of the 17 cases (94%), the association between the AEFI and mRNA-vaccination was considered possible by the pharmacovigilance centre.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Number of cases of suspected drug- or vaccine-induced myocarditis, perimyocarditis and pericarditis reported to the RPVC from 2012 until July 2021.
Blue bars and blue lettering indicate the number of myocarditis and perimyocarditis cases, green bars and green lettering indicated the number of pericarditis cases.
Figure 2.
Figure 2.. Short-axis (upper line) and long-axis (lower line) CMR images of a young patient with acute myocarditis.
In the first two columns, cine-SSFP images are shown in diastole and systole and suggest absence of any wall motion abnormality. In the next column, T2-weighted edema images demonstrate the presence of patchy focal edema in the sub-epicardium of the inferolateral wall (red arrows). In the last column, T1-weighted LGE images demonstrate presence of sub-epicardially distributed LGE (red arrows) which is typical for acute myocarditis.

References

    1. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. American Journal of Physiology. Heart and Circulatory Physiology. 2020;318(5):H1084–H1090. - PMC - PubMed
    1. Evans PC, Rainger GE, Mason JC, Guzik TJ, Osto E, Stamataki Z, Neil D, Hoefer IE, Fragiadaki M, Waltenberger J, Weber C, Bochaton-Piallat ML, Bäck M. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovascular Research. 2020;116(14):2177–2184. - PMC - PubMed
    1. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, Van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology. 2004;203(2):631–637. - PMC - PubMed
    1. Sawalha K, Abozenah M, Kadado AJ, Battisha A, Al-Akchar M, Salerno C, Hernandez-Montfort J, Islam AM. Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome. Cardiovascular Revascularization Medicine: Including Molecular Interventions. 2021;23:107–113. - PMC - PubMed
    1. Su YB, Kuo MJ, Lin TY, Chien CS, Yang YP, Chou SJ, Leu HB. Cardiovascular manifestation and treatment in COVID-19. Journal of the Chinese Medical Association: JCMA. 2020;83(8):704–709. - PMC - PubMed

LinkOut - more resources